Aurobindo Pharma Q2 Profit Surges 33% to ₹1,126 Cr; Revenue Up 24%; ₹7 Dividend

The Quick Take

• Net profit rose 32.8% YoY to ₹1,126 crore in Q2 FY27, versus ₹848 crore a year earlier
• Revenue grew 24% to ₹10,263 crore, compared to ₹8,286 crore in the prior-year period
• Board declared an interim dividend of ₹7 per share payable by November 20 to shareholders

Aurobindo Pharma's Q2 FY27 results cement its position among India's top-performing generics exporters. The company's consolidated net profit surged 32.8% year-on-year to ₹1,126 crore while revenue climbed 24% to ₹10,263 crore, both beating expectations. This performance comes as the broader Indian pharmaceutical sector navigates mixed signals, with US generics pricing under selective pressure and domestic formulations growth moderating. Aurobindo's simultaneous margin expansion and revenue acceleration reflect disciplined cost control alongside a deepening US formulations portfolio spanning both oral solid-dose and injectable segments.

The strong beat will pressure peers including Sun Pharma, Dr. Reddy's, Cipla, and Lupin to match comparable margins in upcoming quarterly results, potentially lifting the Nifty Pharma index broadly. The board's declaration of a ₹7 interim dividend by November 20 signals management confidence in cash generation. Foreign institutional investors holding Indian pharma positions will likely interpret the results as validation of generics export durability. Supply-chain participants, including active pharmaceutical ingredient manufacturers in India's pharma cluster, may also benefit from continued high-volume procurement as Aurobindo scales formulations capacity.

Investors should watch Q3 FY27 guidance and any commentary on US FDA inspection status at Aurobindo's key manufacturing facilities, which remain the most critical variable for sustaining export momentum. Any new drug application approvals or competitive entry into injectables and complex generics will indicate whether revenue growth can hold above 20%. The macro variable is US generic drug pricing policy under the new administration — broadly supportive conditions maintain Aurobindo's pricing power, while aggressive mandated pricing compression would narrow margins across the Indian generics exporter cohort.

Synthesized from 2 sources.